Vanguard Growth Index Fund ETF vs Zoetis Inc — how do they compare? Vanguard Growth Index Fund ETF trades at $88.89, while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Vanguard Growth Index Fund ETF pays none, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VUG | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.29 | $156.76 |
52-Week Low | $70.00 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Vanguard Growth ETF (VUG) trades at $88.87, down 0.35% today, with a bullish technical outlook supported by moving averages. The ETF shows strong institutional accumulation, with multiple firms increasing positions by over 500% in Q2 2026. Technical indicators show overbought RSI levels but strong trend momentum with ADX readings above 30.
VUG offers exposure to large-cap growth stocks with historical outperformance versus the S&P 500. Risks include growth stock volatility and concentration in technology sectors. The ETF remains attractive for long-term investors seeking growth exposure, though current overbought conditions suggest potential for near-term consolidation.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →